Nuvectis Pharma (NVCT) reported second-quarter 2026 financial results, including a net loss of $7.0 million, compared with $6.3 million a year earlier. Cash and cash equivalents were $22.2 million as of June 30, 2026, before a July follow-on offering that raised $115 million in gross proceeds.
The company said it completed in-licensing of ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco. Ciprocopan was approved in China in July 2026 for PNH patients previously untreated with complement inhibitors, and U.S. regulatory work is underway.
- Cash: $22.2 million at June 30, 2026, compared with $31.6 million at Dec. 31, 2025.
- Offering: Nuvectis raised $115 million in gross proceeds in July, which the company said extends cash runway into 1H 2029.
- Expenses: R&D expenses were $4.7 million, up from $3.6 million a year earlier; G&A expenses were $2.5 million, down from $3.0 million.
- Ciprocopan: A pre-IND meeting with the FDA followed by IND submission is expected in 4Q2026.
- NXP200: A Phase 1b trial in China is ongoing, with U.S. IND submission expected in 4Q2026.
- NXP900: Combination studies in NSCLC and a planned pancreatic cancer investigator-sponsored trial remain part of the oncology program.
$NVCT Insider Trading Activity
$NVCT insiders have traded $NVCT stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NVCT stock by insiders over the last 6 months:
- MARLIO CHARLES MOSSERI purchased 50,000 shares for an estimated $916,000
- RON BENTSUR (Chairman & CEO) purchased 12,500 shares for an estimated $250,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NVCT Hedge Fund Activity
We have seen 35 institutional investors add shares of $NVCT stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- IRIDIAN ASSET MANAGEMENT LLC/CT added 125,321 shares (+19.2%) to their portfolio in Q2 2026, for an estimated $2,304,653
- CITADEL ADVISORS LLC added 78,425 shares (+inf%) to their portfolio in Q1 2026, for an estimated $606,225
- UBS GROUP AG added 30,188 shares (+360.5%) to their portfolio in Q1 2026, for an estimated $233,353
- MARSHALL WACE, LLP added 29,223 shares (+inf%) to their portfolio in Q1 2026, for an estimated $225,893
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 28,868 shares (-21.5%) from their portfolio in Q1 2026, for an estimated $223,149
- STRS OHIO added 27,200 shares (+inf%) to their portfolio in Q2 2026, for an estimated $500,208
- OCCAM CREST MANAGEMENT LP added 27,147 shares (+7.1%) to their portfolio in Q1 2026, for an estimated $209,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
